Sec Form 4 Filing - Hove Anders D @ Anacor Pharmaceuticals, Inc. - 2016-04-14

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Hove Anders D 2. Issuer Name and Ticker or Trading Symbol Anacor Pharmaceuticals, Inc. [ ANAC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O VENROCK, 3340 HILLVIEW AVE. 3. Date of Earliest Transaction (MM/DD/YY) 04/14/2016 (Street) PALO ALTO, CA94304 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 04/14/2016 C( 1 ) 257,647 A $ 31.05 353,881 ( 2 ) I By Funds and LLC's ( 3 ) Common Stock 33,886 D ( 4 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares 2.00% Convertible Senior Notes due 2021 $ 31.05 04/14/2016 C ( 5 ) 10/15/2021 Common Stock 257,647 $ 0 $ 0 I By Funds and LLC's

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Hove Anders D C/O VENROCK 3340 HILLVIEW AVE. PALO ALTO, CA94304 X Signatures /s/ Anders D. Hove 04/15/2016 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The conversions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Venrock Healthcare Capital Partners, L.P. ("VHCP"), VHCP Co-Investment Holdings, LLC ("VHCP Co-Invest"), Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), VHCP Co-Investment Holdings II, LLC ("VHCP Co-Invest II"), Venrock Associates IV, L.P. ("VA4"), Venrock Partners, L.P. ("VP") and Venrock Entreprenerus Fund IV, L.P. ("VEF4") on March 16, 2016. ( 2 )The shares are held as follows: 44,464 shares held by VA4, 9,068 shares held by VP, 1,092 shares held by VEF4, 100,521 shares held by VHCP, 18,383 shares held by VHCP Co-Invest, 151,658 shares held by VHCP II, and 28,695 shares held by VHCP Co-Invest II. ( 3 )Venrock Management IV, LLC ("VM4"), Venrock Partners Management, LLC ("VPM") and VEF Management IV, LLC ("VEFM4") are the sole general partners of VA4, VP and VEF4, respectively, and may be deemed to beneficially own these shares. VHCP Management, LLC ("VHCP Management") is the general partner of VHCP and the manager of VHCP Co-Invest and may be deemed to beneficially own these shares. VHCP Management II, LLC ("VHCP Management II") is the general partner of VHCP II and the manager of VHCP Co-Invest II and may be deemed to beneficially own these shares. Anders Hove is a member of VM4, VPM and VEFM4 and a managing member of VHCP Management and VHCP Management II. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP, VEF4, VHCP, VHCP Co-Invest, VHCP II, VHCP Co-Invest II, VM4, VPM, VEFM4, VHCP Management and VHCP Management II except to the extent of his indirect pecuniary interest therein. ( 4 )The reporting person is a member of VR Management, LLC (the "Management Company"). Under an agreement between the reporting person and the Management Company, the reporting person is deemed to hold an aggregate of 794 of the reported securities for the sole benefit of the Management Company (the "Management Company Shares"). The Management Company may be deemed the indirect beneficial owner of the Management Company Shares, and the reporting person may be deemed the indirect beneficial owner of the Management Company Shares through his interest in the Management Company. The reporting person disclaims beneficial ownership of the Management Company Shares except to the extent of his indirect pecuniary interest therein. ( 5 )The 2.00% Convertible Senior Notes due 2021 were convertible into common stock at a conversion price equal to $31.05 (32.2061 shares of common stock for each $1,000 worth of principal) on the date of conversion.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.